Table 1: Main characteristics and results of the eligible studies for evaluation of overall survival.

Study
(author/year)
CountryNumber of patientsAge (y)
Median (range)
ALP cut-off (IU/L)Enneking stageHR (95% CI)Follow-up (m)
Median (range)

Aparicio et al., 1999 [25]Spain3317 (12–42)115II1.26 (0.42–3.74)96 (60–156)
Foukas et al., 2002 [26]UK4518 (6–48)NAIIB3.44 (1.52–7.79)68 (28–88)
Ford et al., 2004 [27]UK350NS (<40)NAII1.66 (1.09–2.51)NA
Bramer et al., 2005 [28]UK89NANAII1.49 (0.72–3.06)NA
Mialou et al., 2005 [29]France6013.5 (2–19)500IIIB2.2 (1.2–4.1)NA
Yalçın et al., 2008 [30]Turkey5513 (7–17)NAII-III1.1 (0.5–2.41)NA
Chou et al., 2009 [31]USA91NANAIII3.16 (1.77–5.36)89 (1–141)
Kim et al., 2009 [32]Korea6715.7 (3.8–644)NAII1.37 (0.54–3.45)59.9
Wu et al., 2009 [33]Taiwan ROC9120.2 (5–84)AII-III2.52 (1.32–4.75)58.2 (2–233)
Yao et al., 2009 [34]China5716 (6–70)136II-III3.45 (1.4–8.46)32.5 (10–52)
Hagleitner et al., 2011 [35]Netherlands9417.8 (4.5–39.5)NAII-III1.66 (0.88–3.11)67.2 (28.8–360)
Ferrari et al., 2012 [36]Italy20914 (4–39)AII1.69 (0.98–2.9)76 (31–115)
Han et al., 2012 [37]China17723.2 (5–57)AII1.80 (1.28–2.51)87 (8–144)
Durnali et al., 2013 [38]Turkey21120 (13–74)AII-III1.75 (1.23–2.5)30.5 (0.5–213)
Min et al., 2013 [39]China33319 (5–78)NAII-III1.73 (1.28–2.33)NA (1–100)
Hung et al., 2015 [40]Taiwan ROC6913.5 (3.8–17.7)150II-III3.08 (1.05–9.08)51.6 (18–111.6)
Berner et al., 2015 [41]Norway301NAAII-III1.64 (1.22–2.19)NA

NA: not available, A: available (see the footnotes for details), HR: hazard ratio, CI: confidence interval, y: year(s), and m: month(s).
: 2 times of upper limit normal level.
: ALP cut-off: 2–10 y 100–350 IU/L; 10–13 y female 110–400 IU/L; 13–15 y male 125–500 IU/L; 20–50 y 25–100 IU/L; other childhood age 73–300 IU/L.
§: ALP cut-off: >18 y 150 IU/L; <18 y 110 IU/L.
Δ: ALP cut-off: 0–17 y 400 IU/L; >17 y 105 IU/L.